Cancer Causes Control (2017) 28:971–979 DOI 10.1007/s10552-017-0929-4 BRIEF REPORT Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma 1,2 1 1 3 • • • Ellen T. Chang Edmund C. Lau Fionna S. Mowat M. Jane Teta Received: 12 January 2017 / Accepted: 20 July 2017 / Published online: 28 July 2017 Springer International Publishing AG 2017 Abstract Conclusions The increase in second primary mesothelioma Purpose This large, population-based U.S. study of lym- risk following radiotherapy for lymphoma is independent phoma patients followed for up to four decades enables of several patient and disease characteristics, and is higher detailed analysis of second primary mesothelioma risk after with earlier treatment era and longer latency. radiotherapy. Methods U.S. Surveillance, Epidemiology, and End Keywords Hodgkin lymphoma Non-Hodgkin Results data were used to identify second primary lymphoma Mesothelioma Radiotherapy Epidemiology mesothelioma among patients diagnosed with Hodgkin SEER Program lymphoma (HL) or non-Hodgkin lymphoma (NHL) between 1973 and 2014. Standardized incidence ratios (SIRs) were calculated by radiotherapy. Multivariate Introduction adjusted associations were examined using competing risks survival analysis. Ionizing radiation, a known human carcinogen, has been Results Among 47,219 HL patients (19,538 irradiated) and used since the 1950s
Cancer Causes & Control – Springer Journals
Published: Jul 28, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera